MedCity News August 27, 2024
Johnson & Johnson announced last week a major change in the way it offers 340B pricing for two medications. The change is “inconsistent” with the 340B statute, according to HRSA.
In a letter last week, Johnson & Johnson informed certain hospitals of a major change it plans to make in the way it gives out discounts on two drugs. The company has found itself in opposition to hospital groups, and the federal government is planning to take action.
Starting October 15, Johnson & Johnson announced that it will stop providing upfront discounts to disproportionate share hospitals (DSH) participating in the 340B Drug Pricing Program for the plaque psoriasis drug Stelara and the blood thinner Xarelto. Instead, these hospitals will need...
Today's Sponsors
Today's Sponsor